CTLA-4 variant immunomodulatory proteins and uses thereof
AssigneeAlpine Immune Sciences, Inc.
InventorsLawrence Evans, Joseph L Kuijper, Ryan Swanson
Life of this patent
Estimating the term…
Abstract
Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.
Claims23
A variant CTLA-4 polypeptide, comprising one or more amino acid substitutions with reference to the extracellular domain of an unmodified CTLA-4 polypeptide or a specific binding fragment thereof comprising an IgV domain, wherein the one or more amino acid substitutions are selected from among M87T, L12F, R16H, I18T, A26T, S27P, E33V, T37S, M56T, M56V, L63H, L91R, and N110K, corresponding to positions set forth in SEQ ID NO:2, and wherein the variant CTLA-4 polypeptide specifically binds to the ectodomain of human CD80.
A variant CTLA-4 polypeptide comprising one or more amino acid substitutions with reference to the extracellular domain of an unmodified CTLA-4 polypeptide or a specific binding fragment thereof comprising an IgV domain, wherein the variant CTLA-4 polypeptide comprises the sequence of amino acids set forth in any of SEQ ID NOS:
- 158, 161, 163, 173, 179, 195, 210, 275, 623, 628, 629, 630, 631, 632, 633 or a specific binding fragment thereof.
Dependencies are inferred from the claim text.